[Retracted] Clinical Evaluation of Levetiracetam in the Treatment of Epilepsy

Table 1

Composition and pathogenesis of each group.

Group	Cases	Gender composition	Average age/years	Acute intracranial infection/case	Traumatic brain injury/case	Cerebrovascular disease/case	Self-withdrawal and poor control/case	Autoimmune encephalitis/case	CJD/case
Sodium valproate control group	60	30/30	41	44 (73.3%)	2 (3.3%)	3 (5.0%)	9 (15%)	2 (3.3%)	0
500 mg/d levetiracetam	34	18/16	38	20 (58.8%)	1 (2.9%)	3 (8.8%)	8 (23.5%)	2 (5.8%)	0
1000 mg/d levetiracetam	54	28/26	39	35 (64.8%)	1 (1.8%)	6 (11.1%)	7 (12.9%)	3 (5.5%)	2 (3.7%)
1500 mg/d levetiracetam	25	15/10	36	14 (56.0%)	1 (4.0%)	2 (8.0%)	5 (20.0%)	2 (8.0%)	1 (4.0%)